A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Clinical trial NCT05622058 · TERMINATED
Trial details
- NCT number
- NCT05622058
- Sponsor
- Aileron Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-09
- Primary completion
- 2023-02-22
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.